Dutasteride vs Finasteride: What the Trials Actually Show

Is dutasteride better than finasteride for hair loss?

In the two head-to-head trials, dutasteride 0.5 mg beat finasteride 1 mg on hair count at 24 weeks with similar rates of adverse events. Both trials stopped at 24 weeks. Finasteride has five-year data behind it and regulatory approval in most countries; dutasteride has neither outside a few Asian markets, and stays in the body about sixty times longer.

Dutasteride vs finasteride is the most useful question in male pattern hair loss, and the one most pages answer badly. The usual treatment is a paragraph on how each drug works, a sentence saying dutasteride is stronger, and a shrug about talking to your doctor. That skips the two things that decide it: how much extra hair the stronger drug actually buys, and what you are accepting in exchange.

Both are 5-alpha reductase inhibitors. Both work by cutting dihydrotestosterone, the hormone that shrinks follicles in people genetically sensitive to it. Neither grows hair the way minoxidil does. They stop or slow the process that is taking it away, which is why they are the backbone of medical treatment and why stopping them undoes the result.

Table of contents

• The actual difference between the two drugs
• Dutasteride vs finasteride: the head-to-head trials
• The comparison in one table
• The trial that was never run
• Side effects: what the labels and trials report
• The half-life difference nobody mentions
• Approval status, cost and access
• So which one, and for whom
• What to ask at the appointment

The actual difference between the two drugs

The difference is which enzymes each drug blocks. There are two relevant forms of 5-alpha reductase, type 1 and type 2. Finasteride inhibits type 2 only. Dutasteride inhibits both, which is why it suppresses more DHT.

The ISHRS puts the numbers at about 98% serum DHT suppression for dutasteride against 71% for finasteride. It also flags the pharmacokinetic gap that shapes everything else about the two drugs: the half-life is "5 weeks for dutasteride" and "6-8 hrs for finasteride".

That is not a small difference in convenience. It is a difference in how reversible your decision is. Finasteride clears in days. Dutasteride takes months to leave the body, which cuts both ways: it forgives a missed dose, and it forgives nothing if you develop a side effect and want the drug gone.

Neither drug does anything about follicles that are already gone. Both are most useful earlier in the process, which is worth establishing before choosing between them. If you have not placed your own pattern yet, the Norwood stage finder is the standard scale, and the difference between stage 3 and stage 5 changes what treatment is realistically on the table.

Dutasteride vs finasteride: the head-to-head trials

Two proper randomised trials have compared them directly, and dutasteride won both on hair count.

Olsen et al, J Am Acad Dermatol 2006. 416 men aged 21 to 45, randomised to dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo, daily for 24 weeks. Dutasteride increased target area hair count over placebo dose-dependently, and dutasteride 2.5 mg was superior to finasteride at both 12 and 24 weeks (PubMed). Note the doses: this trial used finasteride 5 mg, the prostate dose, not the 1 mg hair loss dose.

Gubelin Harcha et al, J Am Acad Dermatol 2014. The larger and more relevant one. 917 men aged 20 to 50, randomised to dutasteride 0.02, 0.1 or 0.5 mg, finasteride 1 mg, or placebo, for 24 weeks. Dutasteride 0.5 mg significantly increased hair count and hair width and improved photographic hair growth compared with finasteride 1 mg (p = 0.003, p = 0.004 and p = 0.002) and with placebo (all p < 0.001). The paper reports that "the number and severity of adverse events were similar among treatment groups" (PubMed).

Sereepanpanich et al, JAAD International 2025. A newer pilot that asks a question the big trials did not: what if you use dutasteride's long half-life deliberately? Sixty men were randomised to dutasteride 0.5 mg twice weekly, dutasteride 0.5 mg thrice weekly, or finasteride 1 mg daily for 24 weeks. Mean terminal hair count change was 7.74, 17.43 and 12.81 hairs/cm² respectively. Thrice-weekly dutasteride produced moderate-to-marked improvement in 35% of men against 21% on daily finasteride, but the authors are careful to state that thrice-weekly dutasteride "did not significantly increase hair count over finasteride 1 mg daily" (PubMed). It was a 60-man unblinded pilot, so it is a lead rather than a conclusion.

The comparison in one table

	Finasteride 1 mg	Dutasteride 0.5 mg
Blocks	Type 2 5-alpha reductase	Type 1 and type 2
Serum DHT suppression (ISHRS)	About 71%	About 98%
Half-life	6 to 8 hours	About 5 weeks
Approved for hair loss	Yes, in most countries	South Korea, Japan and Taiwan only
Longest efficacy evidence	5 years, 1,553 men randomised	24 weeks
Head-to-head result on hair count	Lower	Higher (p = 0.003 at 24 weeks)
Sexual adverse events in trials	1.3% to 1.8% year one, vs 0.7% to 1.3% placebo	Similar rates to finasteride in the same trials
Blood donation deferral (US)	1 month after last dose	6 months after last dose
Typical US cash price	Roughly $10 to $30 a month	Roughly $10 to $30 a month

The trial that was never run

Here is the thing that no comparison page says out loud: there is no long-term head-to-head trial. Both direct comparisons stopped at 24 weeks, which is barely past the point where hair growth drugs start showing their effect.

What finasteride has instead is duration. The five-year multinational study randomised 1,553 men across two phase III trials, with 1,215 continuing into four one-year extensions, and found durable improvement against placebo on every endpoint while the placebo group lost hair progressively. A separate real-world series of 3,177 Japanese men found an overall hair growth effect in 87.1% of the 2,561 men assessed, with the response rate improving the longer treatment continued, and adverse reactions in 0.7%.

Dutasteride has nothing comparable for hair loss. It has years of safety data at the same 0.5 mg dose from prostate medicine, which is genuinely reassuring about the drug, and 24 weeks of hair data.

So the comparison people want, "which drug leaves you with more hair in ten years", has not been tested. What has been tested is which drug produces more hair in six months. Those are different questions, and anyone claiming dutasteride is "X% better" long term is extrapolating across studies with different endpoints, durations and populations.

The practical reading: dutasteride's advantage at 24 weeks is real and statistically significant. Whether it compounds, plateaus or narrows over five years is unknown.

Side effects: what the labels and trials report

Both drugs carry the same category of risk, and the trial numbers are lower than the internet suggests while the uncertainty is higher than the labels suggest.

The Propecia label reports these drug-related adverse experiences in year one of the controlled trials, against placebo:

Adverse experience	Finasteride 1 mg	Placebo
Decreased libido	1.8%	1.3%
Erectile dysfunction	1.3%	0.7%
Ejaculation disorder	1.2%	0.7%
Decreased volume of ejaculate	0.8%	0.4%
Discontinued because of a sexual adverse experience	1.2%	0.9%

The label states that "resolution occurred in men who discontinued therapy with PROPECIA due to these side effects and in most of those who continued therapy". It also lists, from postmarketing reports rather than trials, sexual dysfunction that continued after discontinuation, depression, suicidal ideation and behaviour, male breast cancer, and male infertility or poor seminal quality.

Those two paragraphs sit on the same label and they are the honest shape of the problem. In randomised trials the excess over placebo is around half a percentage point per symptom. In postmarketing reports, which are voluntary, uncontrolled and cannot establish causation or frequency, persistent symptoms after stopping are described. The ISHRS notes that most hair surgeons "had never seen permanent side effects" while acknowledging conflicting data on frequency. Neither the trials nor the reports settle it, and a page that offers you certainty in either direction is not being straight with you.

For dutasteride specifically, the 917-man trial found adverse events similar in number and severity across groups. The ISHRS cites a double-blind study in which 2 of 70 patients on 0.5 mg daily had decreased libido and 2 of 70 had impotence. It also reports a fertility signal that finasteride does not carry as clearly: a 25% to 28% decrease in sperm count during a one-year trial, with a 23% reduction still present six months after stopping. If you are trying to conceive, that number belongs in the decision.

One practical point for men over 40 on either drug: finasteride causes a median 40% decrease in serum PSA in men aged 40 to 49 and a median 50% decrease in men aged 50 to 60. PSA is the prostate cancer screening marker, so anyone taking either drug needs their doctor to know, or a normal-looking result may be masking something.

Neither drug is prescribed to women of childbearing age, because both can cause abnormal development of a male fetus. Women should not handle crushed or broken tablets. Both drugs are prescription-only in most countries for exactly these reasons.

The half-life difference nobody mentions

Five weeks versus eight hours has consequences that rarely make it into a comparison article.

Stopping is slow. If you develop a side effect on finasteride, the drug is functionally gone in days and you learn quickly whether it was the cause. On dutasteride, a meaningful washout takes months. That asymmetry is the strongest practical argument for trying finasteride first, and it has nothing to do with efficacy.

Blood donation. The American Red Cross defers donors for 1 month after the last dose of finasteride and 6 months after the last dose of dutasteride, because both can cause birth defects and a transfusion could expose a pregnant recipient. Regular donors should factor in that dutasteride costs them roughly half a year of eligibility after they stop.

Intermittent dosing is plausible. Because dutasteride accumulates, some clinicians prescribe it two or three times a week rather than daily, and the 2025 pilot above is the first randomised attempt to test that. Thrice-weekly outperformed twice-weekly on both density and diameter. It is not established practice, but it is the reason a dutasteride prescription may not say "one daily".

Approval status, cost and access

Finasteride 1 mg is approved for male pattern hair loss in most countries. Dutasteride is approved for hair loss only in South Korea, Japan and Taiwan; everywhere else it is licensed for benign prostatic hyperplasia and prescribed off label for hair. Off label is legal and routine, but it means the dose, the monitoring and the risk conversation rest on your prescriber's judgement rather than on a regulator's review of hair loss data.

Cost is not the deciding factor for either. Both are old generics, and both run roughly $10 to $30 a month at US pharmacies with a discount card. Telehealth subscriptions charge more for the same molecules plus a consultation, which is a convenience purchase rather than a different product.

What does cost real money is what comes after medication stops being enough. Drugs protect what you have; they do not rebuild a hairline lost years ago. If you are weighing indefinite medication against a one-off procedure, price both properly rather than guessing, and our hair transplant cost calculator breaks a transplant down by graft count and country, and the cost of borrowing for it is priced out in our guide to hair transplant financing. Worth knowing before that conversation: surgery does not end the medication. A transplant redistributes hair, so the untransplanted hair keeps thinning unless something is holding it.

So which one, and for whom

The evidence supports a straightforward default and two reasons to depart from it.

Finasteride first, in most cases. It is approved for the indication, it has five years of randomised data plus large real-world series behind it, and it clears the body in days if it does not suit you. Starting with the reversible drug that has the deepest evidence base is the conservative order, and conservative is appropriate for a cosmetic indication treated indefinitely.

Dutasteride when finasteride is not holding the line. The 24-week head-to-head data is real: more hair count, more hair width, better photographic assessment, similar adverse event rates. For someone losing ground on finasteride, that is a rational escalation and a common one.

Neither, if the pattern is past what a drug can address. DHT blockers preserve and partially restore. They do not resurrect a scalp that has been bare for a decade, and no comparison between the two drugs matters at that point.

One thing both drugs share: they are maintenance. Stopping either is typically followed by significant shedding of the hair that was gained and preserved. The decision is not which drug to take for a year. It is which drug to take for the foreseeable future, which is exactly why the reversibility difference deserves more weight than it usually gets. Many treatment plans also pair a DHT blocker with a growth stimulant, since the two work on different mechanisms, and the options there are covered in our guide to oral minoxidil.

What to ask at the appointment

• Given my stage and how fast I am losing, is a DHT blocker the right first step at all?
• If we start finasteride, how long before we judge whether it is working, and what will we measure?
• What would make you switch me to dutasteride, and what dose and frequency would you use?
• I am planning to have children: how does that change your recommendation?
• I am over 40: how will this affect my PSA results, and who needs to know?
• If I get a side effect, what is the plan, and how long until the drug is out of my system?

This is general information, not medical advice, and no article can weigh your history the way a clinician can. If you are choosing between these two drugs, that decision belongs with a dermatologist or a hair restoration surgeon who can examine your scalp and read your bloods.

Frequently Asked Questions

Is dutasteride stronger than finasteride?

Yes, in the sense that it suppresses more DHT, about 98% against 71% according to the ISHRS, because it blocks both type 1 and type 2 5-alpha reductase rather than type 2 alone. In the 917-man head-to-head trial that translated into significantly higher hair count and width at 24 weeks. No trial has compared them beyond 24 weeks.

Can you switch from finasteride to dutasteride?

Switching is common when finasteride is no longer holding the line, and it is a standard escalation rather than an unusual step. Because dutasteride has a half-life of about five weeks against six to eight hours for finasteride, the change is much harder to reverse quickly, which is the main reason clinicians usually try finasteride first.

Do dutasteride and finasteride have the same side effects?

They share the same category of sexual and mood-related adverse effects, and the head-to-head trials reported similar numbers and severity across groups. Dutasteride carries a clearer fertility signal, with a reported 25% to 28% drop in sperm count over a year and a 23% reduction persisting six months after stopping, which matters for anyone trying to conceive.

What happens if you stop taking finasteride or dutasteride?

Hair that the drug was maintaining is generally lost, and the ISHRS notes that abrupt stoppage of either drug is usually followed by significant shedding of the hair that was gained and preserved. Both drugs are maintenance treatments rather than cures, so the decision to start one is effectively a decision to continue indefinitely.